The Efficacy of Pemigatinib in Advanced NSCLC With FGFR Aberration: Case Report

•Pemigatinib has demonstrated significant efficacy as a second-line treatment for patients with FGFR abnormalities in advanced cholangiocarcinoma. •There are currently no proven drugs specifically targeting FGFR aberration in patients with advanced NSCLC. •The results suggest that pemigatinib could be considered for patients with FGFR-aberrant advanced lung cancer and further research is warranted to identify the specific FGFR aberrations that may be more responsive to pemigatinib. •Pemigatinib has demonstrated significant efficacy as a second-line treatment for patients with FGFR abnormalities in advanced cholangiocarcinoma. •There are currently no proven drugs specifically targeting FGFR aberration in patients with advanced NSCLC. •The results suggest that pemigatinib could be considered for patients with FGFR-aberrant advanced lung cancer and further research is warranted to identify the specific FGFR aberrations that may be more responsive to pemigatinib.